Related Experiment Video
Updated: Mar 22, 2026
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Pluripotent Stem Cell Therapy in Ischemic Cardiovascular Disease
Ting-Hsing Chao1, I-Chih Chen2, Shi-Ya Tseng3
1Division of Cardiology, Department of Internal Medicine, National Cheng Kung University College of Medicine and Hospital, Tainan; ; Division of Cardiology, Department of Internal Medicine, National Cheng Kung University College of Medicine and Hospital, Dou-Liou Branch, Yun-Lin County;
Unlabelled:
Stem cell therapy has been viewed as a promising therapeutic strategy in ischemic cardiovascular disease for almost a decade. Although many progenitor/stem cells obtained from patients have been investigated, and are alleged to be suitable for autologous transplantation, their therapeutic application has been limited by their inability to yield a sufficient number of stem cells, as well as impaired regeneration capacity from ageing and cardiovascular risk factors. Pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), have the capacity for functional multi-lineage differentiation and properties of self-renewal and immortality, and can generate clinically relevant amounts of stem cells. The regeneration capacity of these cells is not affected by ageing. Patient-specific pluripotent stem cells, iPSCs, can be established by epigenetically reprogramming somatic fibroblasts. iPSCs and iPSC-derived stem cells share similar phenotypes and gene expressions of ESCs and ESC-derived stem cells. Transplantation of pluripotent stem cell-derived endothelial cells, mural cells, cardiomyocytes, or cardiovascular progenitor cells contribute to neovascularization and cardiomyogenesis with better limb perfusion and recovery of myocardial contractility in the preclinical studies. Several strategies have been developed to enhance the efficacy of reprogramming and engrafting, and improve graft survival, proliferation, and electromechanical coupling by tissue engineering. However, the therapeutic application of ESCs and derivatives is limited by ethical concerns. Before wide clinical application of these cells in regeneration therapy occurs, substantial effort should be undertaken to discover the most promising cell type and derivatives, the best protocol regarding cell preparation, reprogramming and differentiation, and the most efficacious methods to avoid adverse effects.
Key Words:
Embryonic stem cells; Induced pluripotent stem cells; Limb ischemia; Myocardial infarction.
Insights
Pluripotent stem cells, like embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), offer a promising approach for treating ischemic cardiovascular disease, overcoming limitations of traditional stem cells.
Area of Science:
- Cardiovascular Regenerative Medicine
- Stem Cell Biology
- Ischemic Cardiovascular Disease Therapeutics
Background:
- Traditional stem cell therapies for ischemic cardiovascular disease face limitations due to insufficient cell numbers and impaired regeneration in aged or at-risk patients.
- Pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), possess self-renewal and multi-lineage differentiation capabilities, unaffected by age.
- Patient-specific iPSCs can be generated via epigenetic reprogramming of somatic cells, offering a potential autologous source for regenerative therapies.
Purpose of the Study:
- To evaluate the potential of pluripotent stem cells and their derivatives for treating ischemic cardiovascular diseases.
- To explore strategies for enhancing the efficacy and safety of pluripotent stem cell-based therapies.
- To address challenges hindering the clinical translation of these advanced regenerative approaches.
Main Methods:
- Investigated the differentiation capacity of ESCs and iPSCs into cardiovascular lineages (endothelial cells, cardiomyocytes, etc.).
- Assessed the therapeutic effects of transplanted pluripotent stem cell derivatives in preclinical models of limb ischemia and myocardial infarction.
- Explored tissue engineering strategies to improve cell engraftment, survival, and electromechanical coupling.
Main Results:
- Transplantation of pluripotent stem cell-derived cardiovascular cells promoted neovascularization and cardiomyogenesis in preclinical studies.
- Improved limb perfusion and recovery of myocardial contractility were observed following transplantation.
- Tissue engineering approaches showed potential in enhancing graft performance and survival.
Conclusions:
- Pluripotent stem cells and their derivatives represent a powerful tool for cardiovascular regeneration, overcoming limitations of traditional stem cells.
- Further research is crucial to optimize cell preparation, reprogramming, differentiation protocols, and to mitigate potential adverse effects for clinical application.
- Ethical considerations surrounding ESCs necessitate careful evaluation, while iPSCs offer a promising alternative for patient-specific regenerative strategies.
Related Concept Videos
01:13Induced Pluripotent Stem Cells
01:06Induced Pluripotent Stem Cells
Somatic...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:22iPS Cell Differentiation
01:17Stem Cell Culture